newsfilter
← Latest News
GlobeNewswire·

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent